Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Altus Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,560,370

405 payments

Through program year 2024, Altus Research Inc is reported as receiving $1,560,370 in research payments, across 405 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $143,361 56
2023 Research $206,003 73
2022 Research $497,498 60
2021 Research $118,073 36
2020 Research $105,683 35
2019 Research $489,752 145

Breakdown

Who paid Research payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $425,286 24 payments
  2. AbbVie, Inc. $193,194 101 payments
  3. Eisai Inc. $143,648 47 payments
  4. Mylan Inc. $120,617 29 payments
  5. Sumitomo Pharma America, Inc. $117,286 51 payments
  6. Pfizer Inc. $112,319 20 payments
  7. Mylan Technologies Inc. $79,536 6 payments
  8. Astellas Pharma Global Development $77,743 26 payments
  9. Novo Nordisk AS $76,795 10 payments
  10. Regeneron Pharmaceuticals, Inc. $55,401 17 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Phase III, Randomized, Open-Label, Controlled, Multi-Center Study to $395,795 19 payments
  2. M16-283 $153,775 73 payments
  3. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors $143,648 47 payments
  4. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $120,617 29 payments
  5. A Phase 3 Randomized Doubleblind Placebocontrolled 26Week Multicenter Study With A 78Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo $82,375 13 payments
  6. Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $79,536 6 payments
  7. A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms $77,743 26 payments
  8. Nn9924-4257 $75,281 8 payments
  9. Serene $67,270 26 payments
  10. A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability $34,959 13 payments
What the money was spent on Research payments · program years 2019–2024
  1. Patient care $4,187 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record